This is the authors' abstract. We don't add key points for this paper.
The purpose of this article is to review the current state of pharmacoeconomics and reimbursement for pharmacogenomics (PGx) and to discuss the challenges and opportunities for integrating PGx into routine clinical practice. The author begins by providing an overview of the principles of pharmacoeconomics and the key factors that influence reimbursement decisions. The author also discusses the current state of reimbursement for PGx testing by different payers.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sara L. Rogers (2023) studied this question.
Synapse has enriched 9 related papers. Consider them for comparative context: